A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia

NCT00002258 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sandoz